Attention: This platform is in beta mode. Expect some changes and adjustments.

AI Market Mood: Stock Dashboard

ALT


Fundamental

Company: Altimmune Inc
Sector: Healthcare
Industry: Biotechnology
Country: USA
Exchange: NASD
Index: RUT
P/E: -
EPS (ttm): -1.25
Insider Own: 1.04%
Shs Outstand: 81.11M
Perf Week: 3.50%
Market Cap: 455.82M
Forward P/E: -
EPS next Y: -1.35
Insider Trans: 1.32%
Shs Float: 80.26M
Perf Month: 4.85%
Income: -90.24M
PEG: -
EPS next Q: -0.32
Inst Own: 47.38%
Short Float: 28.25%
Perf Quarter: 0.90%
Sales: 0.02M
P/S: 22791.00
EPS this Y: 5.73%
Inst Trans: -5.86%
Short Ratio: 8.96
Perf Half Y: -36.06%
Book/sh: 1.83
P/B: 3.08
EPS next Y Percentage: -7.13%
ROA: -52.22%
Short Interest: 22.67M
Perf Year: -23.85%
Cash/sh: 1.85
P/C: 3.04
EPS next 5Y: 0.60%
ROE: -57.28%
52W Range From: 3.55
52W Range To: 11.16
Perf YTD: -22.05%
Dividend Est.: -
P/FCF: -
EPS past 5Y: 3.48%
ROI: -62.88%
52W High: -49.64%
Beta: 0.58
Dividend TTM: -
Quick Ratio: 15.82
Sales past 5Y: -67.83%
Gross Margin: -700.00%
52W Low: 58.18%
ATR (14): 0.34
Dividend Ex-Date: Jan 20, 2017
Current Ratio: 15.82
EPS Y/Y TTM: 21.09%
Oper. Margin: -490965.00%
RSI (14): 53.52
Volatility W: 1.50%
Volatility M: 3.41%
Employees: 59
Debt/Eq: 0.01
Sales Y/Y TTM: -95.12%
Profit Margin: -451200.00%
Recom: 1.20
Target Price: 22.38
Option/Short: Yes / Yes
LT Debt/Eq: 0.01
EPS Q/Q: 24.79%
Payout: -
Rel Volume: 1.52
Prev Close: 5.46
Sales Surprise: -
EPS Surprise: 26.12%
Sales Q/Q: 0.00%
Earnings: May 13 BMO
Avg Volume: 2.53M
Price: 5.62
SMA20: 0.21%
SMA50: 9.06%
SMA200: -14.29%
Trades:
Volume: 3,851,067
Change: 2.93%

Technical:


Latest News:

Analysts' Top Healthcare Picks: Adverum Biotechnologies (ADVM), Gilead Sciences (GILD) somewhat bullish
ADVM GILD CVRX

Summary: Analysts are bullish on Adverum Biotechnologies (ADVM), Gilead Sciences (GILD), and CVRx (CVRX) in the Healthcare sector.

Full article
2025-02-13T15:11:42Z
Seattle DJC.com local business news and data - Business - CVS Health reports strong 4th quarter somewhat bullish
CVS

Summary: CVS Health beats profit expectations on Wall Street despite rising costs in its insurance division.

Full article
2025-02-13T14:01:01Z
These Analysts Boost Their Forecasts On CVS Health Following Upbeat Earnings very bullish
CVS

Summary: CVS Health Corp reported upbeat earnings for its fourth quarter, beating revenue consensus and exceeding adjusted EPS expectations. The company provided a positive outlook for fiscal year 2025.

Full article
2025-02-13T13:54:21Z
Why CVS Health Corp. (CVS) Surged On Wednesday - Yahoo Finance very bullish
CVS

Summary: CVS Health Corp. (NYSE:CVS) surged by 14.95 percent on Wednesday after announcing an optimistic outlook for its performance in 2025 despite mixed earnings results in the last quarter of 2024.

Full article
2025-02-13T13:33:47Z
CVS Health price target raised to $73 from $68 at Wells Fargo - TipRanks.com somewhat bullish
CVS

Summary: Wells Fargo raises price target on CVS Health (CVS) to $73 from $68, keeps Overweight rating due to better than expected Q4 results and in-line 2025 guidance.

Full article
2025-02-13T11:57:19Z
Disneyland 70th Anniversary Experiences Revealed, Walt Disney Audio-Animatronic Show Delayed somewhat bullish
DIS

Summary: Disneyland is set to introduce exciting experiences for its 70th anniversary in 2025, including the debut of the Walt Disney Audio-Animatronic show and a tribute to the Sherman Brothers. The celebrations will also feature a new gallery experience showcasing the evolution of Walt Disney's dream of Disneyland, and collaborations with The Walt Disney Family Museum showcasing artifacts related to Walt Disney.

Full article
2025-02-13T10:17:51Z
CVS Health Corp (CVS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ... somewhat bullish
CVS

Summary: CVS Health Corp (NYSE: CVS) has shown progress in stabilizing its Aetna business, particularly in Medicare Advantage, which is expected to improve margins. The CFO noted improvements in Medicare trends and expressed caution for 2025, focusing on understanding membership mix changes.

Full article
2025-02-13T07:27:50Z
CVS Health makes turnaround with Q4 earnings beat - BNN Bloomberg somewhat bullish
CVS

Summary: CVS Health reports a quarterly earnings beat with turnaround analysis by senior managing partner at Meridian Equity Partners Jonathan D. Corpina

Full article
2025-02-13T06:48:30Z
Pfizer Gains 6%; BSE HEALTHCARE Index Up 1.3% Thu, 13 Feb 10:51 - Equitymaster very bullish
PFE

Summary: Pfizer stock price surges by 6%, BSE HEALTHCARE Index up by 1.3% with notable gainers being SUVEN PHARMACEUTICALS and Aurobindo Pharma, Pfizer's net profit drops YoY, BSE Sensex and NSE Nifty show positive movements.

Full article
2025-02-13T06:22:19Z
CVS Health Corporation's stock price skyrockets to $63.22, marking a robust 14.95% surge somewhat bullish
CVS

Summary: CVS Health Corporation's stock price soared by 14.95% to $63.22 after beating quarterly profit estimates. Analysts have differing views on the company, with some leaning bearish and others presenting a bullish outlook. Smart Scores indicate a positive long-term outlook for CVS Health Corp.

Full article
2025-02-13T04:41:39Z
Can iPhone, Apple Watch and AirPods detect health changes? Here's what the new study suggests somewhat bullish
AAPL

Summary: Apple has announced the launch of the Apple Health Study in collaboration with leading research institution Brigham and Women’s Hospital, aiming to explore the connections between technology and various aspects of health.

Full article
2025-02-13T03:04:15Z
Earnings: CVS Health reports a sharp fall in Q4 profit; revenue up 4% | AlphaStreet somewhat bearish
CVS

Summary: CVS Health Corporation reported mixed results for Q4 2024 with modest revenue growth and a sharp decline in earnings.

Full article
2025-02-13T02:47:39Z